Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1260779-19-8 | MDL No. : | MFCD12962560 |
Formula : | C5H12ClN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | SSAZHJCPZLEHSD-UHFFFAOYSA-N |
M.W : | 121.61 | Pubchem ID : | 53399270 |
Synonyms : |
|
Num. heavy atoms : | 7 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 33.45 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.17 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.23 |
Log Po/w (WLOGP) : | 1.48 |
Log Po/w (MLOGP) : | 1.14 |
Log Po/w (SILICOS-IT) : | 1.07 |
Consensus Log Po/w : | 0.99 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.3 |
Solubility : | 6.05 mg/ml ; 0.0498 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.37 |
Solubility : | 5.14 mg/ml ; 0.0423 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.02 |
Solubility : | 11.5 mg/ml ; 0.0948 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: C5H11N*ClH With triethylamine In dichloromethane at -78℃; for 0.0833333h; Stage #2: trifluoromethylsulfonic anhydride In dichloromethane at -78℃; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 3 steps 1.1: thionyl chloride / 0.5 h / Reflux 2.1: ammonium hydroxide / tetrahydrofuran / 0 °C 3.1: borane-THF / tetrahydrofuran / 0 - 70 °C 3.2: 1 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1.1: ammonium hydroxide / tetrahydrofuran / 0 °C 2.1: borane-THF / tetrahydrofuran / 0 - 70 °C 2.2: 1 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1.1: triethylamine / dichloromethane / 0.08 h / -78 °C 1.2: -78 °C 2.1: palladium diacetate; t-Boc-L-valine; silver carbonate; sodium 2,2,2-trifluoroacetate / <i>tert</i>-butyl alcohol / 18 h / 80 °C / Sealed tube |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
6.2 mg | Stage #1: (1-methylcyclopropyl)methanamine hydrochloride; C29H23F4N3O6 With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 4h; Stage #2: With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 2h; | 76 Method G General procedure: In a 2-dram vial equipped with a stir bar was added the compound from step a (52 mg, 0.073 mmol). The solid was dissolved in DMF (0.37 mL, 0.20 M), and cyclopropylamine (7.76 µl, 0.110 mmol) was added. Hunig's base (32.0 µl, 0.183 mmol) was added followed by HATU (33.5 mg, 0.088 mmol) in one portion. The reaction was purged with nitrogen and monitored by LCMS until complete (2.5 hrs). The reaction was diluted with EtOAc and quenched with water. Extracted with EtOAc using a phase separator cartridge. ESI-MS m/z: 748.3 [M+H]+(TBS alcohol). |
22 % | With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane Inert atmosphere; | 76 Method G General procedure: In a 2-dram vial equipped with a stir bar was added the compound from step a (52 mg, 0.073 mmol). The solid was dissolved in D14F (0.37 mL, 0.20 M), and cyclopropylamine (7.76 p1, 0.110 mmol) was added. Hunig’s base (32.0 pi, 0.183 mmol) was added followed by HATU(33.5 mg, 0.088 mmol) in one portion. The reaction was purged with nitrogen and monitored by LCMS until complete (2.5 hrs). The reaction was diluted with EtOAc and quenched with water. Extracted with EtOAc using a phase separator cartridge. ESI-MS m/z: 748.3 [M+H] (TBS alcohol). |
[ 177352-26-0 ]
Cycloheptylmethanamine hydrochloride
Similarity: 0.81
[ 89381-08-8 ]
2-Cyclopropylethanamine hydrochloride
Similarity: 0.81
[ 178033-78-8 ]
(S)-1-Cyclopropylethan-1-amine hydrochloride
Similarity: 0.78
[ 58714-85-5 ]
Cyclopentylmethanamine hydrochloride
Similarity: 0.76
[ 97291-62-8 ]
trans-2-Methylcyclopropanamine hydrochloride
Similarity: 0.76
[ 177352-26-0 ]
Cycloheptylmethanamine hydrochloride
Similarity: 0.81
[ 89381-08-8 ]
2-Cyclopropylethanamine hydrochloride
Similarity: 0.81
[ 178033-78-8 ]
(S)-1-Cyclopropylethan-1-amine hydrochloride
Similarity: 0.78
[ 58714-85-5 ]
Cyclopentylmethanamine hydrochloride
Similarity: 0.76
[ 97291-62-8 ]
trans-2-Methylcyclopropanamine hydrochloride
Similarity: 0.76